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Introduction
TNF-a is involved in regulation of herpes virus replication
and dissemination, and varicella, herpes zoster and herpes
labialis have been observed as adverse events during clini-
cal trials with and in national registries for the use of eta-
nercept in JIA, in some cases resulting in serious adverse
events (saes).
Objectives
The aim of this study was to obtain incidence data of pri-
mary varicella, herpes zoster and herpes labialis in
patients with JIA and to compare incidence rates of
patients receiving etanercept with those of patients trea-
ted with methotrexate (MTX) alone.
Methods
Eighty-five (85) patients with JIA receiving etanercept in
combination with MTX (etanercept/MTX) and 71 patients
receiving MTX alone were enrolled at the Division of
Rheumatology, Bambino Gesù Children’s Hospital, Rome,
Italy. Incidence rates were calculated as the number of
varicella cases, herpes zoster episodes and herpes labialis
episodes per patient-years of follow-up (under specific
treatment).
Results
Mean treatment exposure was 2.17+/-1.57 years for eta-
nercept/MTX (184.85 patient-years of total follow-up
under treatment) and 2.80+/- 1.81 years for MTX
(199.42 patient-years). Crude incidence rates for herpes
labialis were significantly higher among patients receiving
etanercept/MTX (70 episodes in 15 patients) compared
to MTX alone (48 episodes in 10 patients)(0.37 vs 0.24
per patient-year, p = 0.015). We found no significant dif-
ference in crude incidence rates between etanercept/
MTX versus MTX treatment group for primary varicella
infection (0.06 vs 0.05 per patient-year, P > 0.05) and
herpes zoster (0.01 vs 0.005 per patient-year, P > 0.05).
All patients who developed varicella received antiviral
treatment. No complicated varicella infections requiring
hospitalization and no cases of multidermatomal zoster,
herpes zoster ophthalmicus or post-herpetic neuralgia
were reported. In the univariate Kaplan-Meier analysis,
there was a statistically significant association only
between herpes labialis and polyarticular involvement (P:
0.024); multivariate Cox regression analysis did not con-
firm this association.
Conclusion
In our study population the incidence rate for herpes
labialis recurrences was significantly higher in the etaner-
cept/MTX group. Patients with polyarticular JIA more
likely have highly active disease; disease activity may affect
cellular-immunity, which could explain the increased
herpes labialis risk observed in this subgroup of JIA
patients. The main limitations of our study are the size of
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